According to the pharmaceutical and biotechnology industry on the 17th, drug research and development company OsteoNeuroGen is set to hold an extraordinary shareholders’ meeting on the 25th to propose the company’s dissolution. (Image from OsteoNeuroGen webpage)
SEOUL, June 18 (Korea Bizwire) — A string of clinical trial failures is putting severe financial strain on South Korea’s biotech sector, forcing some drug development firms into liquidation or restructuring as investor confidence continues to erode.
On Tuesday, industry sources confirmed that OsteoNeuroGen, a pharmaceutical startup focused on treatments for idiopathic pulmonary fibrosis, will convene an emergency shareholders meeting on June 25 to…
